Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Study of Ibrutinib in Refractory Follicular Lymphoma
2012-004097-26Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in follicular lymphoma (FL) and B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall response rate. Started Nov 2012; status: completed.
02
Drugs
ibrutinib
03
Conditions
follicular lymphoma (FL)B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on 2012-004097-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004097-26.